Doctor AI LLC v. WebMD: Venue Transfer to New Jersey After 134 Days in Georgia
Doctor AI LLC filed a patent infringement action against WebMD LLC in the Middle District of Georgia, asserting US11972865B1 covering an AI-powered symptom checker tool. Within 134 days, Judge Clay D. Land ordered the case transferred to the District of New Jersey under § 1406(a) after Plaintiff conceded venue was improper in Georgia.
AI symptom-checker patent dispute moves from Georgia to New Jersey on venue grounds
Doctor AI LLC initiated this patent infringement action on April 21, 2025, in the United States District Court for the Middle District of Georgia, asserting infringement of US11972865B1 against WebMD LLC. The patent relates to an AI-powered ‘Symptom Checker’ tool — technology central to WebMD’s widely-used consumer health platform. The case was assigned to Judge Clay D. Land, and the operative pleading at the time of transfer was Doctor AI’s second amended complaint.
On August 29, 2025, the Court issued a show-cause order directing Doctor AI to explain why the action should not be transferred to the District of New Jersey under 28 U.S.C. § 1406(a) — the statute governing transfers from districts where venue is improper. Doctor AI conceded that venue was proper in New Jersey under the patent-specific venue statute, 28 U.S.C. § 1400(b), and the case was formally transferred on September 2, 2025. The Georgia court declined to rule on several pending motions, including Plaintiff’s motion to file a corrected second amended complaint and WebMD’s motion to seal, leaving all substantive and procedural matters for the New Jersey court.
The 134-day lifespan in Georgia produced no merits ruling on infringement or validity, meaning the patent’s enforceability remains fully contested. The speed of the venue challenge — and Doctor AI’s swift concession — suggests that WebMD’s counsel identified a fundamental jurisdictional defect early in the proceedings. Whether venue was strategically litigated by WebMD or the Court raised the issue sua sponte on the show-cause order is notable; the public record confirms the Court acted first. The case now continues in New Jersey, where WebMD has 14 days post-transfer to answer or otherwise respond.
Filing to Case Transferred in 134 days
134 days from filing to transfer — faster than the median district court patent case resolution
Case transferred to New Jersey: what the venue ruling means for both parties
What a § 1406(a) transfer means — and what it does not
A transfer under 28 U.S.C. § 1406(a) occurs when a court finds venue is improper and elects to transfer rather than dismiss. It is not a merits ruling — no finding on infringement, validity, or damages was made. The case continues in the transferee court (here, District of New Jersey) as if refiled there, preserving all claims and defenses. The Georgia court’s refusal to rule on pending motions is standard practice: all unresolved issues travel with the case.
Venue defect, not meritsDoctor AI keeps its claims alive — but loses home-court advantage
By conceding improper venue and agreeing to transfer rather than face dismissal, Doctor AI preserved its infringement claims under US11972865B1. The case restarts procedurally in New Jersey, including a fresh opportunity to file a corrected second amended complaint. However, the patent holder now litigates in a forum it did not originally choose and must re-engage before a new judge. Timing and cost implications from the Georgia phase are sunk costs that did not advance the merits.
Claims survive, new forumWebMD escapes Georgia — gains procedural reset in New Jersey
WebMD successfully shifted the litigation to the District of New Jersey, a venue where it presumably has a stronger nexus under 28 U.S.C. § 1400(b). The Georgia court granted WebMD a 14-day window post-transfer to respond to the second amended complaint, preserving full defensive options. WebMD’s motion to seal and other pending motions were deferred to New Jersey, giving its legal team a fresh start before a new court without prejudice from Georgia proceedings.
Favourable forum shiftAI-powered symptom checking remains contested IP territory
The transfer does not resolve the underlying question: does WebMD’s Symptom Checker tool infringe US11972865B1? For digital health platforms and AI triage tool developers, this case signals that AI-assisted diagnostic interfaces are active enforcement targets. The District of New Jersey — home to significant pharmaceutical and technology IP litigation — will now adjudicate the scope of AI symptom checker patent claims, a decision that could set persuasive precedent across the digital health sector.
Digital health AI patent riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | DOCTOR AI LLC | Company | AI-driven medical technology IP holder — owner of US11972865B1 covering symptom checker systemsSearch in Eureka ↗ |
| Defendant | Webmd, LLC | Company | WebMD LLC — major consumer digital health platform operator and symptom checker providerSearch in Eureka ↗ |
| Plaintiff counsel | Azad Kabir | Attorney | Counsel for DOCTOR AI LLCSearch in Eureka ↗ |
| Defendant counsel | JEFFERSON M STARR | Attorney | Counsel for Webmd, LLCSearch in Eureka ↗ |
| Defendant counsel | MICHAEL P ADAMS | Attorney | Counsel for Webmd, LLCSearch in Eureka ↗ |
| Defendant counsel | STEVEN MCMAHON ZELLER | Attorney | Counsel for Webmd, LLCSearch in Eureka ↗ |
| Presiding judge | Judge CLAY D. LAND | Judge | Georgia Middle District CourtSearch in Eureka ↗ |
Official order — verbatim text
The transfer order reflects a purely procedural disposition: the Georgia Middle District found venue improper under 28 U.S.C. § 1406(a) and elected transfer over dismissal. No infringement finding, claim construction ruling, or validity determination was issued. The court’s decision to defer all pending motions — including amendment, sealing, and extension requests — to the District of New Jersey signals a clean handoff with no binding rulings that would constrain the transferee court. Both parties effectively restart substantive litigation in New Jersey.
US11972865B1 — AI-powered symptom checker and medical triage technology
US11972865B1, with application number US15/356933, protects an AI-powered system relating to symptom checking and automated medical guidance — the core technology underlying consumer-facing digital health triage tools. The patent issued to Doctor AI LLC and sits within the expanding domain of AI-assisted clinical decision support. Its application history suggests development during the early wave of machine-learning integration into consumer health platforms, placing it at the intersection of natural language processing, medical ontology, and diagnostic inference.
From a competitive standpoint, US11972865B1 is strategically significant because it targets functionality central to high-traffic consumer health platforms. WebMD’s Symptom Checker is among the most widely used tools of its kind globally, making any valid patent covering this functionality commercially material. For the broader digital health sector — including telemedicine platforms, health system patient portals, and AI triage startups — this patent represents a potential enforcement vector that warrants monitoring. The outcome of the New Jersey litigation will clarify whether the claimed AI methods read on commercially deployed symptom-checking architectures.
Should you run an FTO against US11972865B1 before deploying an AI symptom checker?
Any organisation developing or deploying an AI-powered symptom checker, medical triage chatbot, or automated diagnostic guidance tool should treat US11972865B1 as a priority FTO target. Doctor AI LLC has demonstrated willingness to enforce this patent against a major commercial platform, and the claims — now heading to full adjudication in New Jersey — have not been invalidated or limited by any court ruling. Product teams at digital health platforms, EHR vendors, and consumer wellness apps should assess whether their symptom-checking logic or AI triage workflows fall within the patent’s claim scope before commercial launch or expansion.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US11972865B1 against your product architecture in minutes — identifying overlapping claims, relevant prior art, and design-around opportunities. Eureka’s patent family analysis also surfaces any continuation or divisional applications that may extend the enforcement footprint beyond the granted patent. For R&D teams building AI diagnostic interfaces, running a proactive FTO now — before the New Jersey court defines claim scope — is significantly lower risk than responding to a cease-and-desist later.
Run a freedom-to-operate analysis on US11972865B1 to assess your product’s exposure
Run FTO in Eureka →Similar AI medical software patent cases in U.S. district courts
Explore related patent infringement actions involving AI-assisted medical diagnosis and symptom-checker technology litigated in U.S. district courts, including the District of New Jersey.
What this case signals for the digital health AI IP landscape
A venue defect ended the Georgia phase, but the substantive IP battle over AI symptom checker technology is very much alive in New Jersey.
Verify § 1400(b) venue before filing any patent suit — especially against large tech platforms
The patent-specific venue statute, 28 U.S.C. § 1400(b), requires that the defendant either reside in or have committed acts of infringement and maintain a regular place of business in the chosen district. Doctor AI’s concession that Georgia was improper is a costly reminder: filing in a convenient or plaintiff-friendly forum without confirming § 1400(b) compliance wastes time, money, and strategic positioning.
AI diagnostic and symptom-checker patents are entering active enforcement phase
US11972865B1 targeting a Symptom Checker tool reflects a broader pattern of AI-assisted medical triage patents moving from prosecution to enforcement. Digital health platforms, consumer-facing symptom tools, and AI clinical decision-support systems should treat this case as an early signal — freedom-to-operate analysis on AI diagnostic method claims is no longer optional for market-facing products.
DOCTOR v Webmd — key questions answered
Doctor AI LLC sued WebMD LLC in the Middle District of Georgia for infringement of US11972865B1, covering an AI-powered symptom checker tool. After 134 days, the court issued a show-cause order on venue. Doctor AI conceded that venue was improper in Georgia and agreed to transfer. The case was transferred to the District of New Jersey on September 2, 2025, with no merits ruling issued in Georgia.
US11972865B1 is a U.S. patent held by Doctor AI LLC relating to AI-powered symptom checking and automated medical triage technology. Application number US15/356933 underlies the grant. The patent is asserted against WebMD’s ‘Symptom Checker’ tool, a consumer-facing product that guides users through potential diagnoses based on reported symptoms using AI-assisted logic.
The Georgia Middle District Court ordered Doctor AI to show cause why the case should not be transferred under 28 U.S.C. § 1406(a), which governs transfers from districts where venue is improper. Doctor AI conceded that venue was improper in Georgia and that New Jersey was a proper venue under the patent-specific venue statute, 28 U.S.C. § 1400(b). The court transferred the action accordingly.
The Georgia court declined to rule on three pending motions before transfer: Doctor AI’s motion for leave to file a corrected second amended complaint, WebMD’s motion to seal, and any other pending motions. All were deferred to the District of New Jersey. WebMD was granted 14 days post-transfer to answer or otherwise respond to the operative second amended complaint.
The transfer is purely procedural and does not resolve any substantive patent issues. No infringement finding, claim construction order, or validity ruling was issued in Georgia. WebMD’s exposure under US11972865B1 remains fully contested and will be adjudicated by the District of New Jersey. The case continues with the second amended complaint as the operative pleading, and Doctor AI may seek further amendments before the New Jersey court.
PatSnap Eureka searches patents and litigation data to answer instantly.